Quoin Pharmaceuticals (QNRX) Proxy Filing summary

Executive summary

• The annual general meeting is scheduled for December 5, 2024, with seven key proposals up for shareholder vote, including director elections, amendments to the Articles of Association, executive and director compensation, auditor appointment, and approval for the CEO to serve as both CEO and Chairman for three years.

• Shareholders of record as of October 21, 2024, are eligible to vote, with each ordinary share and ADS entitled to one vote per share.

• The board recommends voting in favor of all proposals and has provided detailed proxy materials and annual reports for review.

Voting matters and shareholder proposals

• Proposals include electing seven directors, amending the Articles of Association, approving compensation programs for the CEO and COO, revising non-employee director compensation, appointing Marcum LLP as auditor, and approving the CEO's dual role.

• Amendments to the Articles of Association align quorum and shareholder proposal thresholds with updated Israeli regulations.

• Shareholders holding at least 10% of voting rights may now demand a special general meeting, and quorum requirements are updated to 33 1/3% unless the company qualifies as a foreign private issuer.

Board of directors and corporate governance

• The board consists of seven members, with five qualifying as independent under Nasdaq rules.

• Three standing committees: Audit, Compensation, and Nominating and Governance, each with defined charters and independent membership.

• Board and committee meetings were well attended, and a board diversity matrix is disclosed.

• The nominating process emphasizes integrity, expertise, and diversity, with annual evaluations.